How much funding has Faron Pharmaceuticals raised?

Faron Pharmaceuticals has raised $23.2M in total funding, most recently a Venture Round.

Who are Faron Pharmaceuticals's investors?

Faron Pharmaceuticals's investors include European Innovation Council Fund, Business Finland.

When was Faron Pharmaceuticals founded?

Faron Pharmaceuticals was founded in 2007.

Where is Faron Pharmaceuticals headquartered?

Faron Pharmaceuticals is headquartered in Turku.

What industry is Faron Pharmaceuticals in?

Faron Pharmaceuticals operates in Biotech.

How many employees does Faron Pharmaceuticals have?

Faron Pharmaceuticals has 11-50 employees.

Faron Pharmaceuticals

Innovative immunotherapy for cancers with unmet medical needs.

Turku · Founded 2007 · $23.2M raised

Biotech

Headquarters: Turku
Employees: 11–50
Founded: 2007
Business Model: B2B

Website: faron.com
Total Funding: $23.2M
Last Round: $15.0M Venture RoundFeb 2021
Rounds: 4

About

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy treatments for cancers with significant unmet medical needs. Based in Turku, Finland with an office in Boston, Massachusetts, Faron's lead asset is bexmarilimab, a novel anti-Clever-1 antibody that reprograms the tumor microenvironment by switching immune suppression to immune activation. Bexmarilimab targets Clever-1, a receptor on immunosuppressive macrophages and malignant blasts, and is currently being investigated in multiple clinical trials for hematological malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), as well as solid tumors. In Phase I/II BEXMAB clinical trials, bexmarilimab has demonstrated an 85% overall response rate and 45% complete response rate in frontline higher-risk MDS patients, with median complete response duration of 16.1 months. Faron is listed on the London Stock Exchange AIM market under the ticker FARN and on Nasdaq First North Growth Market under the ticker FARON.

Summary

Faron Pharmaceuticals is a Biotech company based in Turku, founded in 2007. It has raised $23.2M in total across 4 rounds, most recently a $15.0M Venture Round round in Feb 2021. Investors include European Innovation Council Fund and Business Finland.